The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
- Alternative Payment Models
- Biopharmaceutical Innovation
- Elements of Value
- Evidence for Decision Making
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- Patient Centered Formulary & Benefit Design
- Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- Utilization Management & Step Therapy
- Value-Based Insurance Design
- Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Showing 110 Results
NPC Comments on CMS Information Collection Request for Negotiation Data Elements
NPC's comments offer input on the agency's latest efforts to implement the drug price-setting provisions of the Inflation Reduction Act through the design of a data collection process.
NPC Comments on CMS Medicare Drug Price Negotiation Program
NPC's comments highlight concerns about the agency's guidance regarding the implementation of Medicare Drug Price Negotiation and the potential for unintended consequences, including less…
NPC Comments on CMS's Hospital Outpatient Prospective Payment Systems Proposed Rule
NPC comments raise potential concerns as CMS states its intent to make significant changes to the payment rate for drugs purchased through the 340B program.
NPC Comments on CMS CY 2023 Payment Policies under the Physician Fee Schedule
NPC's comments offer input on CMS's implementation of the Discarded Drug Refund Policy, support continuing the add-on payment for at-home COVID-19 vaccinations, and provide recommendations on the…
NPC Comments on CMS Request for Information on the Medicare Program
NPC's comments to CMS's recent request for information on the Medicare program focus on access, innovation and the importance of patient engagement.
NPC Comments on the Medicare Program's Hospital Inpatient Prospective Payment Systems
NPC's comments to CMS focus on recent proposals related to the transition to National Drug Codes for New Technology Add-on Payments and recommendations regarding payment mechanisms to improve access…
Comments to FTC on Business Practices of PBMs and Their Impact on Pharmacies and Consumers
NPC submitted comments to the Federal Trade Commission encouraging the study of anti-competitive business practices of pharmacy benefit managers and their impact on drug affordability and access.
NPC Comments on HHS Notice of Benefit and Payment Parameters for 2023
NPC offers research-based comments to improve patient access to care and health equity.
NPC Comments on CMS' Proposed Medicare Shared Savings and Physician Fee Policies
NPC offers research-based comments to improve CMS' Merit-based Incentive Payment System Value Pathways and quality measurement.
NPC Reiterates Comments on Medicare Program; Medicare Coverage of Innovative Technology, Definition of “Reasonable and Necessary”
NPC resubmitted comments on a proposed rule to establish a Medicare coverage pathway for medical devices designated as breakthrough by the FDA.
NPC Comments on Most Favored Nation (MFN) Model [CMS-5528-IFC]
NPC explains how using payment models based on pricing in other countries could have a negative impact on patient outcomes, access to treatments and future innovation.
NPC Comments on PCORI's Proposed Principles for the Consideration of the Full Range of Outcomes Data
NPC offered public feedback to PCORI on its new mandate to consider the full range of patient-centered outcomes in its research.
NPC Comments on Medicare Program; Medicare Coverage of Innovative Technology, Definition of “Reasonable and Necessary”
NPC submitted comments on a proposed rule to establish a Medicare coverage pathway for medical devices designated as breakthrough by the FDA.
NPC Comments on CMS Proposed Rule on Medicaid Best Price, Value-based Purchasing
NPC outlines barriers and potential solutions to the broader use of value-based purchasing agreements.